Melatonin Alleviates Neuronal Damage After Intracerebral Hemorrhage in Hyperglycemic Rats

Drug Des Devel Ther. 2020 Jul 2:14:2573-2584. doi: 10.2147/DDDT.S257333. eCollection 2020.

Abstract

Background: This study sought to investigate a novel effect of melatonin in reducing brain injury in an in vivo hyperglycemic intracerebral hemorrhage (ICH) model and further explore the mechanisms of protection.

Methods: Hyperglycemia ICH was induced in Sprague-Dawley rats by streptozocin injection followed by autologous blood injection into the striatum. A combined approach including RNA-specific depletion, electron microscopy, magnetic resonance, Western blots, and immunohistological staining was applied to quantify the brain injuries after ICH.

Results: Hyperglycemia resulted in enlarged hematoma volume, deteriorated brain edema, and aggravated neuronal mitochondria damage 3 days after ICH. Post-treatment with melatonin 2 hours after ICH dose-dependently improved neurological behavioral performance lasting out to 14 days after ICH. This improved neurological function was associated with enhanced structural and functional integrity of mitochondria. Mechanistic studies revealed that melatonin alleviated mitochondria damage in neurons via activating the PPARδ/PGC-1α pathway. Promisingly, melatonin treatment delayed until 6 hours after ICH still reduced brain edema and improved neurological functions. Melatonin supplementation reduces neuronal damage after hyperglycemic ICH by alleviating mitochondria damage in a PPARδ/PGC-1α-dependent manner.

Conclusion: Melatonin may represent a therapeutic strategy with a wide therapeutic window to reduce brain damage and improve long-term recovery after ICH.

Keywords: apoptosis; hyperglycemia; intracerebral hemorrhage; melatonin; mitochondria.

MeSH terms

  • Animals
  • Cerebral Hemorrhage / drug therapy*
  • Cerebral Hemorrhage / metabolism
  • Cerebral Hemorrhage / pathology
  • Disease Models, Animal
  • Hyperglycemia / drug therapy*
  • Hyperglycemia / metabolism
  • Hyperglycemia / pathology
  • Injections, Intraperitoneal
  • Male
  • Melatonin / administration & dosage
  • Melatonin / pharmacology*
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Neurons / drug effects*
  • Neurons / metabolism
  • Neurons / pathology
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / pharmacology*
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Neuroprotective Agents
  • Melatonin

Grants and funding

JM Zhang is supported by the Key Program of Science and Technology Development of Zhejiang Province (2017C03021). Z Wang is supported by Basic Public Interests Research Plan of Zhejiang Province (LGF18H090005). JY Zhou is supported by Basic Public Interests Research Plan of Zhejiang Province (LY18H090001).